Abbvie investor relations

Abbvie is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines. The company's abbvie investor relations is to address complex health challenges and improve the lives of people around the world. Abbvie's primary areas of therapeutic focus include immunology, oncology, neuroscience, virology, and general medicine.

AbbVie Inc. Operator: Good morning, and thank you for standing by. All participants will be able to listen-only until the question-and-answer portion of this call. If you have any objection, you may disconnect at this time. I would now like to introduce Ms. Thank you. You may begin.

Abbvie investor relations

.

Liz Shea: Thanks, Scott.

.

AbbVie supports a strong dividend yield, which should act as valuation support, as the cash flows to support the dividend look secure over the next several years. AbbVie has had to depend on acquisitions to boost its late-stage pipeline, suggesting less successful internal research and development activities. Morningstar brands and products. Investing Ideas. As of Mar 2, am Delayed Price Closed. Unlock our analysis with Morningstar Investor. Start Free Trial.

Abbvie investor relations

AbbVie, Inc. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus HCV and human immunodeficiency virus HIV , neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. This browser is no longer supported at MarketWatch. For the best MarketWatch. Market Data. Latest News All Times Eastern scroll up scroll down. What You Need to Know.

Clip art rainbow

We anticipate continued robust demand for both Ubrelvy and Qulipta this year, including the expansion of Qulipta, the only once daily oral CGRP for prevention of both episodic and chronic migraine into the international markets. We're extremely excited to bring this transformative therapeutic option to patients in Europe and the US once approved. As it pertains to AbbVie's near-term outlook, we are focused on three key priorities. Structural tailwinds. Liz Shea: Good morning, and thanks for joining us. It has a strong presence in various therapeutic areas, including oncology, immunology, and rare diseases. You may begin. We remain confident in our long-term outlook, including a return to robust growth in with a high single-digit CAGR through the end of the decade. In addition to the news release issued this morning, we have also posted slides on our website at investors. Key slides for AbbVie Inc. These new indications have a collective peak sales potential of several billion dollars. Liz Shea: Thanks, Scott. Web app. Plus, we are planning to have up to five additional indications for Rinvoq across several sizable markets that will potentially provide another significant revenue inflection in the second half of this decade and into the s. Edge Newsletter.

.

We're extremely excited to bring this transformative therapeutic option to patients in Europe and the US once approved. Silver Carrie Strom: Thank you, Jeff. By successfully developing and commercializing these pipeline candidates, the company can strengthen its market position and drive revenue growth. In addition to the news release issued this morning, we have also posted slides on our website at investors. We anticipate data readouts for these programs over the next three years, beginning with data from our GCA study this year. We continue to see significant momentum in new prescriptions across all indications following the approval as an adjunctive treatment for major depressive disorder just over a year ago. We also recently provided our complete response submission to the FDA for with an approval decision anticipated in the second quarter. Dow Futures 39, With Phase 3 studies underway in five new indications, giant cell arteritis, lupus, HF, alopecia areata and vitiligo. I'm very pleased with AbbVie's strong performance in FTSE 7, And as Rob just described, we see substantial room for continued growth across each of their currently approved indications. And we plan to discuss the data with regulators in the coming months. Liz Shea: Thanks, Scott.